Core Viewpoint - Tianchen Medical (688013) has experienced a slight decline in stock price, closing at 48.03 yuan, down 0.1% from the previous week, with a current market capitalization of 3.898 billion yuan [1] Group 1: Company Announcements - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. on December 31, 2025, focusing on medical intelligence and information technology, smart medical devices, and market collaboration [2] - The company held its first extraordinary shareholders' meeting of 2026 on January 7, 2026, where the board of directors was re-elected, and new directors were appointed [2][3] - The company announced a change in the quality control reviewer for the 2025 audit from Wang Wei to Jiang Ming, who has relevant professional qualifications and no disciplinary records in the past three years [3][4] Group 2: Board Restructuring - The board of directors completed its re-election, with Chen Wangyu elected as chairman and continuing as general manager, while Tian Guoyu was appointed as financial director and board secretary [3][4] - The new board consists of three non-independent directors, three independent directors, and one employee representative director [3]

（文章来源：证券日报） 证券日报网讯 1月7日，天臣医疗发布公告称，公司2025年度审计机构公证天业因原项目质量控制复核 人王微工作调整，改派姜铭接任，变更已完成交接，不影响年度审计工作。 ...

Group 1 - The core point of the article is that Tianchen Medical announced the approval of the election of the third board of directors during its first extraordinary shareholders' meeting in 2026 [1] Group 2 - The company passed the resolution regarding the election of non-independent directors for the third board of directors [1] - The company also approved the resolution for the election of independent directors for the third board of directors [1]

证券代码：688013 证券简称：天臣医疗 公告编号：2026-004 天臣国际医疗科技股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 天臣国际医疗科技股份有限公司（以下简称"公司"）于2025年8月26日召 开第二届董事会第二十八次会议，于2025年9月12日召开2025年第三次临时股东 会，审议通过《关于公司续聘2025年度审计机构的议案》，同意公司续聘公证天 业会计师事务所（特殊普通合伙）（以下简称"公证天业"）为公司2025年度审 计 机 构 ， 具 体 内 容 详 见 公 司 于 2025 年 8 月 27 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《关于公司续聘2025年度审计机构的公告》（公告编 号：2025-049）。 公司于近日收到公证天业通知，因原项目质量控制复核人工作调整，变更了 项目质量控制复核人。现将具体情况公告如下： 2、诚信记录 姜铭近三年不存在因执业行为受到刑事处罚，受到证监会及其派出机构、行 1 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2026-003 天臣国际医疗科技股份有限公司 关于董事会完成换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》等法律、法规、规范性文件及 《天臣国际医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，天臣国际医疗科技股份有限公司（以下简称"公司"或"天臣医疗"）于2026年 1月7日召开2026年第一次临时股东会，选举产生了3名非独立董事和3名独立董事， 与公司通过职工代表大会选举产生的1名职工代表董事，共同组成公司第三届董 事会。 同日，公司召开第三届董事会第一次会议，选举产生董事长、董事会各专门 委员会委员及主任委员（召集人），并聘任高级管理人员及证券事务代表。现将 相关情况公告如下： 一、董事会换届选举情况 （一） ...

一、 会议召开和出席情况 证券代码：688013 证券简称：天臣医疗 公告编号：2026-002 天臣国际医疗科技股份有限公司 2026年第一次临时股东会决议公告 （一） 股东会召开的时间：2026 年 1 月 7 日 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二） 股东会召开的地点：苏州工业园区东平街 278 号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 20 | | --- | --- | | 普通股股东人数 | 20 | | 2、出席会议的股东所持有的表决权数量 | 42,346,654 | | 普通股股东所持有表决权数量 | 42,346,654 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.6072 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.6072 | （四） 表决方式是否符合《 ...

国浩律师（上海）事务所 关 于 天臣国际医疗科技股份有限公司 2026 年第一次临时股东会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 在审查有关文件的过程中，公司向本所律师保证并承诺，其向本所提供的文 件和所作的说明是真实的，有关副本材料或复印件与原件一致。 公司向本所律师保证并承诺，公司已将全部事实向本所披露，无任何隐瞒、 遗漏、虚假或误导之处。 二零二六年一月 国浩律师（上海）事务所 关于天臣国际医疗科技股份有限公司 2026 年第一次临时股东会之 法律意见书 致：天臣国际医疗科技股份有限公司 天臣国际医疗科技股份有限公司（以下简称"公司"）2026 年第一次临时股 东会于 2026 年 1 月 7 日召 ...

Core Insights - Tianchen Medical (688013) closed at 51.22 yuan on January 5, 2026, with a 6.53% increase and a turnover rate of 3.26% [1] - The company reported a net outflow of 1.708 million yuan from main funds, while retail investors saw a net inflow of 597,400 yuan [1] Financial Performance - For the first three quarters of 2025, Tianchen Medical achieved a main revenue of 244 million yuan, a year-on-year increase of 20.66% [3] - The net profit attributable to shareholders reached 71.9458 million yuan, up 68.29% year-on-year, with a non-recurring net profit of 66.2023 million yuan, increasing by 71.85% [3] - In Q3 2025, the company reported a quarterly main revenue of 87.6631 million yuan, a 26.4% year-on-year increase, and a quarterly net profit of 23.7342 million yuan, up 70.74% [3] - The company's debt ratio stands at 11.3%, with an investment income of 2.556 million yuan and financial expenses of -10.8703 million yuan, resulting in a gross profit margin of 63.22% [3] Financing and Margin Information - On January 5, 2026, Tianchen Medical had a financing buy of 10.4463 million yuan and a financing repayment of 14.4032 million yuan, resulting in a net repayment of 3.9569 million yuan [2] - The company has a financing and margin balance of 2.12 billion yuan [2]

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Group 1 - Maduro denies all charges from the U.S. and claims he is still the President of Venezuela [2] - The U.S. has accused Maduro of drug terrorism conspiracy, cocaine smuggling conspiracy, and possession of firearms [2] - Maduro states he was forcibly taken from his home in Caracas [2] Group 2 - China condemns the U.S. for violating Venezuela's sovereignty and international principles [3] - The U.S. is accused of undermining multilateralism and threatening peace in Latin America and the Caribbean [3] Group 3 - Venezuela's oil exports have nearly dropped to zero due to U.S. sanctions and blockade [4] - The Venezuelan oil company is reducing production and closing some oil fields due to accumulated inventory [4] - Shortages of diluents for blending heavy crude oil are further restricting production activities [4] Group 4 - Trump claims the U.S. must have complete access to Venezuela's resources and asserts U.S. control over the country [5][6] - The U.S. Vice President's residence was attacked, with one suspect arrested [6] Group 5 - High expectations for Chinese stocks with projected annual growth of 15% to 20% in 2026 and 2027 [8] - Corporate earnings in China are expected to grow by 14% and 12% in 2026 and 2027, respectively [8] - Factors driving growth include AI applications, international expansion, and policies to reduce internal competition [8]